[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ecmo\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ecmo":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,40,67,92,132,155,177,205,234],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100568044","a-novel-strategy-of-ecmo-management-using-nafamostat-for-regional-combined-with-low-intensity-systematic-anticoagulation-100568044",false,"NCT06676085","A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation","A Novel Strategy Combined Regional Anticoagulation in Membrane Oxygenator and Low-intensity of Systemic Anticoagulation Applied in Management of Extracorporeal Membrane Oxygenation","Inclusion Criteria:\n\n* age older than 18 years old\n* received ECMO because of severe respiratory failure\n\nExclusion Criteria:\n\n* anticoagulant contraindications\n* cerebral infarction or suspected patients\n* severe hypertension\n* women in gestational and lactational period\n* hemophilia\n* allergic to heparin or Nafamostat\n* unwilling or unable to complete the study","ALL","18 Years",{"count":19,"type":20},140,"ESTIMATED","INTERVENTIONAL",[23],"NA","ECMO is widely used in patients with refractory respiratory and\u002For circulatory failure.The data shows that the incidence of bleeding and thrombotic events is still above 40%,and it is closely related to the increase in mortality rate.Therefore, optimizing ECMO anticoagulation management to reduce bleeding and thrombotic events is a key scientific issue that urgently needs to be addressed.",[26],"ECMO","RECRUITING","2026-06-15",{"date":30,"type":31},"2026-06-17","ACTUAL",{"date":33,"type":31},"2024-11-01",{"date":35,"type":20},"2027-12-31",{"name":37,"class":38},"Beijing Chao Yang Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":39},"100640435","perception---super-early-neuroprognostication-in-ecpr-patients-100640435","NCT07584187","PERCEPTION - Super-Early Neuroprognostication in eCPR Patients","Super-Early Neuroprognostication in eCPR Patients: Feasibility of Automated Pupillometry and Cerebral Near-Infrared Spectroscopy - A Prospective Feasibility Study","PERCEPTION","Inclusion Criteria:\n\n* All patients ≥ 18 years evaluated for eCPR treatment at the Department of Emergency Medicine\n\nExclusion Criteria:\n\n* Return of spontaneous circulation before ECMO initiation.\n* Anatomical infeasibility for measurement, including but not limited to:\n* Severe facial trauma or deformity preventing the placement of the automated pupillometry device.\n* Scalp injuries, dressings, or conditions that interfere with the correct positioning of near-infrared spectroscopy (NIRS) sensors.\n* Pre-existing ocular conditions that preclude reliable pupillometry (e.g., enucleation, opaque cornea, or severe anisocoria unrelated to neurological status).",{"count":49,"type":20},45,"OBSERVATIONAL","Background Extracorporeal cardiopulmonary resuscitation (eCPR) is a rescue therapy for a selected group of patients. Extracorporeal membrane oxygenation (ECMO) is initiated to bypass the cardiac system and bridge time to definitive treatment of the cardiac arrest (CA) origin. eCPR treatment is very time-critical and, if indicated, should be initiated as early as possible. Patient selection for this highly specific treatment is challenging and relies on numerous factors. In the following phase of intensive care treatment, neuroprognostication is performed. However, following current guidelines, this is only recommended 72hours after CA. Once ECMO is initiated, a complex intensive care treatment is expected, without a guarantee for full neurological recovery. There is a recognized clinical need for more precise selection criteria, alongside predictive values, to enable earlier, reliable neuroprognostication.\n\nAim This study aims to investigate whether super-early neuroprognostication before ECMO initiation is feasible. Super-early neuroprognostication will be performed using automated pupillometry and cerebral near-infrared spectroscopy (cNIRS) before ECMO initiation.\n\nMethods Patients evaluated for eCPR treatment at the Department of Emergency Medicine will be included in this study. By a study member not involved in clinical treatment, cNIRS and automated pupillometry will be performed before ECMO initiation and at predefined intervals: 10-20 minutes after ECMO Initiation, 1 hour (±15 minutes), 2 hours (±15 minutes), and 3 hours (±15 minutes). Follow-up measurements will be taken 24 hours (± 6 hours), 48 hours (± 6 hours), and 72 hours ± 6 hours after ECMO initiation. The secondary objective is to interpret the collected data regarding outcome parameters.",[53,54,26,55],"Resuscitation","Extra Corporeal Life Support","Extracorporeal Cardiopulmonary Resuscitation",[57,26,58],"eCPR","CPR","2026-05-12",{"date":61,"type":31},"2026-05-14",{"date":59,"type":31},{"date":64,"type":20},"2028-10",{"name":66,"class":38},"Medical University of Vienna",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":39},"100537175","standby-cannulated-ecmo-for-high-risk-percutaneous-coronary-intervention-100537175","NCT06274411","Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention","Standby Cannulated ECMO Versus Prophylactic ECMO In Patients Undergoing High-Risk Percutaneous Coronary Intervention","ECMO-READY","Inclusion Criteria:\n\n1. Clinicians decide to perform PCI during ECMO support.\n2. Age of ≥18\n3. Patient presents with a compromised ejection fraction of less than 35% or at risk of hemodynamic deterioration, or intervention on the last patent coronary conduit or an unprotected left main artery, or complex 3-vessel disease (SYNTAX score of ≥33)\n4. Informed consent\n\nExclusion Criteria:\n\n1. Subject in cardiogenic shock(need inotrope, pressor or mechanical support to maintain SBP \\>90mmHg)\n2. Presence of moderate to severe aortic insufficiency\n3. Severe peripheral vascular disease\n4. creatinine≥4mg\u002FdL\n5. Liver dysfunction with elevation of liver enzymes and bilirubin levels to ≥ 3x ULN\n6. History of recent (within 1 month) stroke or TIA\n7. Abnormal coagulation(defined as platelet count ≤50000\u002Fmm3 or Fibrinogen ≤1.50g\u002FL)\n8. Allergy or intolerance to heparin, aspirin, ADP receptor inhibitors, or documented heparin induced thrombocytopenia.",{"count":76,"type":20},176,[23],"The goal of this multicenter, randomized trial is to compare standby cannulated ECMO versus prophylactic ECMO in patients undergoing high-risk percutaneous coronary intervention (PCI). The main question it aims to answer is :\n\n• If standby cannulated ECMO as compared with prophylactic ECMO will improve the outcomes in patients undergoing high-risk PCI",[26,80],"High-risk PCI",[26,82],"PCI","2026-05-10",{"date":85,"type":31},"2026-05-13",{"date":87,"type":31},"2025-03-21",{"date":89,"type":20},"2026-12-01",{"name":91,"class":38},"Beijing Anzhen Hospital",{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":17,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":106,"conditions":107,"keywords":118,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":39},"100607835","phase-1-influence-of-personalized-lung-volume-optimization-maneuver-on-lung-function-and-cardiac-performance-in-children-100607835","NCT07193719","Influence of Personalized Lung Volume Optimization Maneuver on Lung Function and Cardiac Performance in Children","Influence of a Personalized Lung Volume Optimization Maneuver on Lung Aeration and Cardiac Performance in Mechanically Ventilated Children","ILOCO","CHD study:\n\nInclusion Criteria\n\n* congenital heart disease\n* surgery with cardiopulmonary bypass\n\nExclusion Criteria:\n\n* single ventricle physiology\n* ECMO\u002FVAD\n* \\\u003C36weeks of gestational age\n* chronic lung disease\n* Endotracheal tube leak \\> 15%\n* lack of informed consent from parents.\n\nECMO study Inclusion Criteria\n\n* patients with respiratory failure on ECMO or at risk for ECMO\n* invasive ventilation\n\nExclusion Criteria:\n\n\\- severe lung hypoplasia or interstitial lung disease","0 Years",{"count":102,"type":20},80,[104,105],"PHASE1","PHASE2","The goal of this randomized interventional clinical trial is to learn if a standardized lung volume optimization maneuver (LVOM) is beneficial in\n\n1. study) children undergoing biventricular repair of their congenital heart disease (CHD) with cardiopulmonary bypass and\n2. study) in children with severe respiratory failure at risk for or need for ECMO.\n\nThe main questions it aims to answer are:\n\nMain hypotheses of CHD study: Does a standardized PEEP-Titration maneuver, to optimize end-expiratory lung volume improve:\n\n* cardiac performance\n* lung function\n\nDoes it make a difference in:\n\n* length of ventilation\n* ventilation\u002Fperfusion mismatch of the lung\n* need for vasopressor support?\n\nMain hypotheses of ECMO study:\n\nDoes a LVOM in children\u002Finfants with severe respiratory failure \u002FARDS\n\n* improve lung compliance and gas exchange\n* facilitate lung protective ventilation according to PALICC-2 guidelines\n* improve lung aeration and V\u002FQ-matching assessed with EIT\n\nDoes it make a difference in\n\n* need for ECMO\n* duration of ECMO runs\n* hemodynamics stability",[108,109,110,111,112,113,114,115,116,117,26],"Congenital Heart Disease","Cardiopulmonary Bypass","Cardiac Surgery","Mechanical Ventilation","Positive End-expiratory Pressure (PEEP)","Lung Volume","Lung Mechanics","Hemodynamic Changes","Children","ARDS",[119,120,121,117,26,122],"cardiopulmonary interactions","end-expiratory lung volume","PEEP titration","cardiopulmonary bypass","2026-04-05",{"date":125,"type":31},"2026-04-09",{"date":127,"type":31},"2025-12-05",{"date":129,"type":20},"2027-12-20",{"name":131,"class":38},"Charite University, Berlin, Germany",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":39},"100583107","early-intra-aortic-balloon-pump-use-after-venoarterial-extracorporeal-membrane-oxygenation-100583107","NCT06872021","Early Intra-aortic Balloon Pump Use After Venoarterial Extracorporeal Membrane Oxygenation","Early Intra-aortic Balloon Pump Use After Venoarterial Extracorporeal Membrane Oxygenation: The EASE-ECMO Randomized Clinical Trial","EASE-ECMO","Inclusion Criteria:\n\n1. Age of ≥18\n2. Cardiogenic shock(defined as a systolic blood pressure of less than 90 mm Hg for more than 30 minutes or the initiation of catecholamines to maintain a systolic pressure of more than 90 mm Hg, an arterial lactate level of more than 3 mmol per liter, and signs of impaired organ perfusion)\n3. Successful implantation of VA-ECMO\n4. Informed consent\n\nExclusion Criteria:\n\n1. SCAI shock stage A or B\n2. Presence of moderate to severe aortic insufficiency or aortic dissection\n3. Severe peripheral vascular disease\n4. Post-cardiotomy cardiogenic shock(non-CABG procedure) or bridging to cardiac procedure(heart transplantation or LVAD).\n5. VA-ECMO for definite non-cardiac causes\n6. Isolated right ventricular failure\n7. V-A ECMO usage confined to the period during surgery or other interventions\n8. Ischemic mechanical complications(eg Ventricular septal defect, papillary muscle rupture)\n9. Extracorporeal cardiopulmonary resuscitation\n10. LVAD, Impella or IABP in situ.\n11. Severe bleeding\n12. Terminal malignancy\n13. Irreversible neurologic injury\n14. Pregnancy or lactation",{"count":141,"type":20},358,[23],"The goal of this multicenter, randomized trial is to compare early early left ventricular unloading by Intra-aortic Balloon Pump (IABP) versus conventional approach in patients with cardiogenic shock (CS) undergoing venoarterial extracorporeal membrane oxygenation (VA-ECMO). The main question it aims to answer is :\n\n• If left ventricular unloading by IABP as compared with the conventional approach will improve the outcomes in patients undergoing VA-ECMO.",[26],[26,146,147],"IABP","LV unloading","2026-03-22",{"date":150,"type":31},"2026-03-24",{"date":148,"type":31},{"date":153,"type":20},"2028-12-01",{"name":91,"class":38},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":175,"locationsCount":39},"100595981","evolution-of-d-dimer-as-a-marker-of-bleeding-risk-on-ecmo-100595981","NCT07039513","EVOLUTION OF D-DIMER AS A MARKER OF BLEEDING RISK ON ECMO","ECMOstase2","Inclusion Criteria:\n\n* Male or female ≥ 18 years of age\n* Hospitalized patient in intensive care\n* Implementation of a VV or VA ECMO for less than 24 hours\n* Patient affiliated to a social protection health insurance scheme\n* Non-opposition by the patient or a relative in the event that the patient is not in a state to express his or her non-opposition or inclusion in an emergency procedure in the event that the patient is not in a state to express his or her non-opposition and no relative of the patient can be reached.\n\nExclusion Criteria:\n\n* Patient on veno-arterial ECMO after cardiac, cardiopulmonary surgery or after placement of a left or biventricular cardiac assist device\n* Congenital hemostasis disorder or anatomical abnormality predisposing to bleeding\n* Dying patient on the day of inclusion\n* Patient under judicial protection\n* Patient under guardianship or curatorship\n* Pregnancy\n* Breastfeeding",{"count":163,"type":20},100,"ECMO (extracorporeal membrane oxygenation) is a life-saving device, used in intensive care to treat severe respiratory or cardiac failure. However, it carries a high risk of serious life-threatening bleeding.\n\nBleeding complications have been attributed to coagulopathy triggered either by the underlying pathology or by the extracorporeal circuit itself, as well as excessive or inappropriate anticoagulation initiated to prevent thrombotic complications.\n\nThe objective of this cohort is to confirm the interest of the evolution of D-dimers as a prognostic marker of serious bleeding events in patients on veno-venous (VV) or veno-arterial (VA) ECMO, and to determine the threshold.",[26,166,167],"Mplementation of a Veno-venous VV or Veno-arterial VA","INTENSIVE CARE","NOT_YET_RECRUITING","2025-11-27",{"date":171,"type":31},"2025-12-01",{"date":169,"type":20},{"date":174,"type":20},"2027-06-01",{"name":176,"class":38},"University Hospital, Strasbourg, France",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":21,"phases":187,"briefSummary":188,"conditions":189,"keywords":194,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100559133","restrictive-versus-liberal-thresholds-for-rbc-transfusion-in-ecmo-100559133","NCT06560164","Restrictive Versus Liberal Thresholds for RBC Transfusion in ECMO","Restrictive Versus Liberal Thresholds for Red Blood Cell Transfusion in ExtraCorporeal Membrane Oxygenation - the TREC Study","TREC","Inclusion Criteria:\n\n* Patient is aged 18 years or older;\n* Is receiving ECMO;\n* (Deferred) informed consent.\n\nExclusion Criteria:\n\n* Not expected to survive for 24 hours when assessed;\n* Inability to receive blood products;\n* (Known) decline to blood transfusions (e.g., Jehovah's Witnesses);\n* Extracorporeal carbon dioxide removal (ECCO2R) using low blood flow devices or pumpless devices (i.e., MINILUNG ®, PrismaLung+);\n* Received ECMO over 48h before screening for eligibility.",{"count":186,"type":20},526,[23],"Rationale: In patients supported with extracorporeal membrane oxygenation (ECMO), transfusion of red blood cells (RBC) is very common. This is possibly due to the application of liberal thresholds and the lack of evidence-based guidelines. Although RBC transfusion can be lifesaving, it is also a risk-bearing intervention with substantial risk for morbidity and mortality in this critically ill population. Also, with increasing scarcity, RBC transfusions are becoming more expensive. Furthermore, in the past decades it has been shown in several critically ill patient populations - not on ECMO - that maintaining a restrictive hemoglobin (Hb) threshold for RBC transfusion is non-inferior, including in cardiothoracic surgery, acute myocardial infarction and septic shock. Therefore, the investigators hypothesize that a restrictive transfusion threshold for RBC is safe to apply in patients on ECMO in comparison with a liberal transfusion threshold.\n\nObjective: The primary objective of this trial is to study in a prospective randomized comparison whether a restrictive RBC transfusions strategy is non-inferior compared to a liberal strategy in patients on ECMO with respect to 90-day mortality.\n\nStudy design: Prospective multi-center randomized controlled non-inferiority trial.\n\nStudy population: Patients, 18 years or older, receiving ECMO.\n\nIntervention: Restrictive RBC transfusion threshold: in case the Hb transfusion trigger of 7.0 g\u002FdL (4.3 mmol\u002FL) is reached, 1 RBC unit at a time will be transfused. The aimed Hb target range of the restrictive\u002Fintervention group will be 7.1 - 9.0 g\u002FdL (4.3 - 5.6 mmol\u002FL). Liberal RBC transfusion threshold: in case the Hb transfusion trigger of 9.0 g\u002FdL (5.6 mmol\u002FL) is reached, 1 RBC unit at a time will be transfused. Target range of the liberal group is defined as Hb 9.1 - 11.0 g\u002FdL\n\nMain study parameters\u002Fendpoints: The primary outcome parameter is 90-day all-cause mortality.\n\nSecondary outcomes include: 1) proportion of patients on ECMO exposed to allogeneic RBC transfusion; 2) RBC volume infused per patient during ECMO; 3) reasons for RBC transfusion other than Hb triggers; 4) transfusion reactions; 5) time on ECMO; 6) length of hospital- and ICU-stay; 7) in-ICU morbidity; 8) quality of life (QoL), iMTA Medical Consumption Questionnaire (iMCQ) and Productivity Cost Questionnaire (iPCQ) at 3, 6, 9, and 12 months; 9) costs related to a) transfusion, b) hospital admission and c) transfusion-related sequelae.",[190,191,192,193,26],"Transfusion","Red Blood Cell","Extracorporeal Membrane Oxygenation","Anemia",[190,191,192,193,26],"2025-04-04",{"date":197,"type":31},"2025-04-08",{"date":199,"type":31},"2024-11-26",{"date":201,"type":20},"2029-10-01",{"name":203,"class":38},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",12,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":214,"conditions":215,"keywords":218,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":39},"100566969","the-ecmocyp-cytochromes-p450-activity-study-100566969","NCT06662084","The ECMOCYP (cytochromes P450 Activity) Study","Impact of Temporary Mechanical Circulatory Support (tMCS) on Cytochromes P450 Activity Measured with Dried Blood Spot","Inclusion Criteria:\n\n* Male and female patients presenting a refractory cardiogenic shock, requiring temporary mechanical circulatory support (tMCS), with either the use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) or a micro-axial pump device (Impella® CP).\n* Male and female patients in cardiogenic shock according to the SCAI (Society for Cardiovascular Angiography and Interventions) ESC (European Society of Cardiology) definition and not requiring or not eligible to temporary mechanical circulatory support (tMCS). (e.g. ECMO, Impella®, intra-aortic balloon pump) (control group)\n* Age \\> 18 years old\n* Comprehension of French\n* Ability to give consent (consent will be sought from the therapeutic representative or from relatives as the patient will be sedated and intubated. Definitive consent will be sought at patient's second blood sample planned after tMCS explantation (in case of patient's favorable outcome).\n\nExclusion Criteria:\n\n* Male and female patients presenting a refractory ARDS requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO)\n* Inability to receive the Geneva cocktail by enteral way\n* Severe or terminal Renal impairment (defined as GFR\\\u003C30ml\u002Fmin according to Cockroft-Gault)\n* Severe chronic hepatic insufficiency (CHILD B-C)\n* Sensitivity to any of the drugs used in the Geneva Cocktail\n* Intake of drugs altering CYPs activity (Strong inhibitor or inducer based on https:\u002F\u002Fwww.hug.ch\u002Fsites\u002Fhde\u002Ffiles\u002Fstructures\u002Fpharmacologie\\_et\\_toxicologie\\_cliniques\u002Fa5\\_cytochromes\\_6\\_2.pdf)",{"count":213,"type":20},46,"Prospective open label observational study including patients requiring a tMCS (VA-ECMO or Impella® CP) or in in cardiogenic shock according to the SCAI (Society for Cardiovascular Angiography and Interventions) ESC (European Society of Cardiology) definition 41,42 and not requiring or not eligible to tMCS (ECMO, Impella®, intra-aortic balloon pump) (control group).",[26,216,217],"Cardiogenic Shock","Temporary Mechanical Circulatory Support",[219,220,217,221,222,223,224],"ecmo","cardiogenic shock","TMCS","CYP450","phenotyping","genotyping","2024-10-25",{"date":227,"type":31},"2024-10-28",{"date":229,"type":20},"2024-10",{"date":231,"type":20},"2026-07",{"name":233,"class":38},"University Hospital, Geneva",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":4},"100532264","precise-treatment-of-ceftazidime-avibactam-in-patients-with-cro-infections-under-the-guidance-of-tdm-and-ppk-model-100532264","NCT06210542","Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model","Inclusion Criteria:\n\n1. 18-85 years old.\n2. Hospitalized participants in ICU who did not receive Ceftazidime Avibactam treatment within 15 days before joining the study.\n3. Participants with severe infection (refer to the 2022 sepsis3.0 guidelines for the definition of severe infection).\n4. at least one carbapenem-resistant Gram-negative pathogen (including but not limited to carbapenem-resistant Enterobacteriaceae and \u002F or Pseudomonas aeruginosa) was confirmed by bacterial culture in the primary infection site samples.\n5. sufficient respiratory secretions, blood and peritoneal effusion can be obtained within 48 hours before the first administration for bacterial culture and drug sensitivity test.\n6. intravenous injection of Ceftazidime Avibactam for more than 72 hours.\n7. understand compliance with research procedures and methods, voluntarily participate in this study, and sign informed consent in writing.\n\nExclusion Criteria:\n\n1. Participants are less than 18.\n2. Death within 72 hours after the start of treatment.\n3. Known resistance to β-lactam antibacterial drugs including cephalosporins, cephalosporin compound preparations containing β-lactamase inhibitors, or Those with a history of allergies to ceftazidime avibactam sodium for injection and its excipients.\n4. No indication for treatment with ceftazidime avibactam.\n5. Pregnant and lactating women.","85 Years",{"count":242,"type":20},50,"The goal of this study is to evaluate the efficacy and safety of ceftazidime-avibactam(CAZ-AVI) in the treatment of critically ill patients with carbapenem-resistant organisms(CRO) infections (including dialysis patients and extracorporeal membrane oxygenation(ECMO) patients).",[26,245],"Carbapenem-Resistant Enterobacteriaceae Infection","2024-01-14",{"date":248,"type":31},"2024-01-18",{"date":250,"type":20},"2024-01",{"date":252,"type":20},"2026-12",{"name":254,"class":38},"Sichuan Provincial People's Hospital"]